Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Sildenafil may benefit some patients with esophageal motility disorders

Some patients with hypercontractile esophageal motility disorders may benefit from sildenafil, although side-effects can be common, claims a team from Graz, Austria.

News image

fiogf49gjkf04

The researchers investigated the effect of sildenafil (Viagra) on esophageal motor function in healthy subjects and patients with hypercontractile esophageal motility disorders.

They reported their results in the June issue of Gut.

A total of 6 healthy male volunteers were enrolled in the randomized double blind study. They participated on 2 separate days, before and 1 hour after oral intake of either sildenafil 50 mg or placebo.

Esophageal manometry was performed to determine vector volume of the lower esophageal sphincter (LOS) and pressure amplitudes of the esophageal body.

Of these volunteers, 4 underwent 12-hour ambulatory esophageal manometry on 2 separate days, once with sildenafil 50 mg and once with placebo.

An activity index for spontaneous swallowing was calculated for every hour of the study.

Sildenafil lowers LOS pressure and propulsive forces in the esophagus body.
Gut

Eleven patients with hypercontractile esophageal motility disorders took part in an open study of the effect of 50 mg sildenafil on manometric features of their disorder. The clinical response to sildenafil was also examined.

In healthy individuals, sildenafil significantly reduced LOS pressure vector volume and pressure amplitudes in the distal half of the esophageal body.

The researchers found that, in 3 of 4 subjects, the inhibitory effect of sildenafil lasted at least 8 hours.

In 9 of the 11 patients with esophageal motor disorders, manometric improvement was observed after taking sildenafil.

However, only 4 of these individuals had an improvement in esophageal symptoms with sildenafil taken as required.

Furthermore, 2 of these 4 patients experienced side-effects and did not want to continue treatment.

Andreas J. Eherer, of the Karl-Franzens University, Graz, said on behalf of the group, "Sildenafil lowers LOS pressure and propulsive forces in the body of the esophagus of healthy subjects, as well as in patients with nutcracker esophagus, hypertensive LOS, and achalasia.

"The effect of sildenafil on the esophageal body may last for up to 8 hours in healthy volunteers."

"A subset of patients with hypertensive LOS or nutcracker esophagus may benefit from sildenafil, but side effects are a limiting factor," it was concluded.

Gut 2002; 50: 758-64
22 May 2002

Go to top of page Email this page Email this page to a colleague

 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us